|
1
|
Wang L, Zhang Q, Wang X, Dong Z, Liu S,
Wang Q, Zhang Z and Xing J: Therapeutic landscape of ovarian
cancer: Recent advances and emerging therapies. Biomark Res.
13:1032025. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shah M, Chen TY, Ison G, Fiero MH, Zhang
H, Gao X, Neilson M, Goldberg KB, Nair A, Ricks TK, et al: Overall
survival and the evolving benefit-risk assessment for poly
(ADP-ribose) polymerase inhibitors in advanced ovarian cancer. J
Clin Oncol. 43:2218–2227. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aggarwal R, Sheikh A, Akhtar M, Ghazwani
M, Hani U, Sahebkar A and Kesharwani P: Understanding gold
nanoparticles and their attributes in ovarian cancer therapy. Mol
Cancer. 24:882025. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu C, Chen D, Stout MB, Wu M and Wang S:
Hallmarks of ovarian aging. Trends Endocrinol Metab. 36:418–439.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gupta R, Kumar R, Penn CA and Wajapeyee N:
Immune evasion in ovarian cancer: Implications for immunotherapy
and emerging treatments. Trends Immunol. 46:166–181. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang Z, Liu Y and Yang Q: Navigating PARP
inhibitor resistance in ovarian cancer: Bridging mechanistic
insights to clinical translation. Curr Treat Options Oncol.
26:797–819. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Therachiyil L, Bhat AA and Uddin S:
Claudins in ovarian cancer: Emerging biomarkers and therapeutic
targets. Tissue Barriers. Aug 13–2025.(Epub ahead of print).
PubMed/NCBI
|
|
8
|
Wang Y, He S, Huang Q, Yang J, Yang C and
Ding J: The roles of YY1 in reproductive system: an overview. Chem
Biol Interact. 417:1115602025. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu J, Wang H, Wan H, Yang J, Gao L, Wang
Z, Zhang X, Han W, Peng J, Yang L and Hong L: NEK6 dampens FOXO3
nuclear translocation to stabilize C-MYC and promotes subsequent de
novo purine synthesis to support ovarian cancer chemoresistance.
Cell Death Dis. 15:6612024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu A, Li S, Feng C, He R, Wu R, Hu Z,
Huang J, Wang W, Huang L and Qiu L: Fn14 Controls the
SIRT2-Mediated deacetylation of slug to inhibit the metastasis of
epithelial ovarian cancer. Adv Sci (Weinh). 12:e25015522025.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao F, Liu G, Xiong L, Yao L, Wang L and
Zhang Z: Effect of sufentanil on the proliferation, apoptosis, and
epithelial-mesenchymal transition of ovarian cancer cells by
regulating the SMAD3/SNAIL signaling pathway. J Mol Histol.
56:992025. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vikramdeo KS, Miree O, Anand S, Sharma A,
Srivastava SK, Singh S, Rocconi RP and Singh AP: MYB/AKT3 axis is a
key driver of ovarian cancer growth, aggressiveness, and
chemoresistance. J Ovarian Res. 18:1792025. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fu Z, Chen K, Zheng F, Gong W, Chao D and
Lu C: FCGBP promotes ovarian cancer progression via activation of
IL-6/JAK-STAT signaling pathway. J Transl Med. 23:8272025.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin J, Liu H, Fukumoto T, Zundell J, Yan
Q, Tang CA, Wu S, Zhou W, Guo D, Karakashev S, et al: Targeting the
IRE1α/XBP1s pathway suppresses CARM1-expressing ovarian cancer. Nat
Commun. 12:53212021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hasan A, Khan NA, Uddin S, Khan AQ and
Steinhoff M: Deregulated transcription factors in the emerging
cancer hallmarks. Semin Cancer Biol. 98:31–50. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bleu M, Mermet-Meillon F, Apfel V, Barys
L, Holzer L, Bachmann Salvy M, Lopes R, Amorim Monteiro Barbosa I,
Delmas C, Hinniger A, et al: PAX8 and MECOM are interaction
partners driving ovarian cancer. Nat Commun. 12:24422021.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheng Q, Li L and Yu M: Construction and
validation of a transcription factors-based prognostic signature
for ovarian cancer. J Ovarian Res. 15:292022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nameki RA, Chang H, Yu P, Abbasi F, Lin X,
Reddy J, Haro M, Fonseca MA, Freedman ML, Drapkin R, et al:
Rewiring of master transcription factor cistromes during high-grade
serous ovarian cancer development. bioRxiv. Apr 12–2023.(Epub ahead
of print). PubMed/NCBI
|
|
19
|
Xiang X, Mao J, Tang D, Huang H and Tang
H: The ZBTB family in cardiac development and diseases. Biochem
Biophys Res Commun. 771:1520262025. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou Y, Chen X and Zu X: ZBTB7A as a
therapeutic target for cancer. Biochem Biophys Res Commun.
736:1508882024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gupta S, Singh AK, Prajapati KS, Kushwaha
PP, Shuaib M and Kumar S: Emerging role of ZBTB7A as an oncogenic
driver and transcriptional repressor. Cancer Lett. 483:22–34. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maeda T, Hobbs RM and Pandolfi PP: The
transcription factor Pokemon: A new key player in cancer
pathogenesis. Cancer Res. 65:8575–8578. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yue R, Chen Y, Lai W and Wei W: miR-106b
exerts tumor suppressive functions in ovarian carcinoma by directly
targeting ZBTB7A. Minerva Med. 112:657–658. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bonome T, Levine DA, Shih J, Randonovich
M, Pise-Masison CA, Bogomolniy F, Ozbun L, Brady J, Barrett JC,
Boyd J and Birrer MJ: A gene signature predicting for survival in
suboptimally debulked patients with ovarian cancer. Cancer Res.
68:5478–5486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Arend RC, Scalise CB, Gordon ER, Davis AM,
Foxall ME, Johnston BE, Crossman DK and Cooper SJ: Metabolic
alterations and WNT signaling impact immune response in HGSOC. Clin
Cancer Res. 28:1433–1445. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Z, Zhan Q, Eckert M, Zhu A,
Chryplewicz A, De Jesus DF, Ren D, Kulkarni RN, Lengyel E, He C and
Chen M: RADAR: Differential analysis of MeRIP-seq data with a
random effect model. Genome Biol. 20:2942019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Geistlinger L, Oh S, Ramos M, Schiffer L,
LaRue RS, Henzler CM, Munro SA, Daughters C, Nelson AC, Winterhoff
BJ, et al: Multiomic analysis of subtype evolution and
heterogeneity in high-grade serous ovarian carcinoma. Cancer Res.
80:4335–4345. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou Q, Tang H, Wang Y, Hua Y, Ouyang X
and Li L: Hyperoside mitigates PCOS-associated adipogenesis and
insulin resistance by regulating NCOA2-mediated PPAR-ү
ubiquitination and degradation. Life Sci. 364:1234172025.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang S, Wang C, Hu Y, Li X, Jin S, Liu O,
Gou R, Zhuang Y, Guo Q, Nie X, et al: ZNF703 promotes tumor
progression in ovarian cancer by interacting with HE4 and
epigenetically regulating PEA15. J Exp Clin Cancer Res. 39:2642020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Du G, Huang X, Su P, Yang Y, Chen S, Huang
T and Zhang N: The role of SOX transcription factors in prostate
cancer: Focusing on SOX2. Genes Dis. 12:1016922025. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Luo Y, Liu X, Chen Y, Tang Q, He C, Ding
X, Hu J, Cai Z, Li X, Qiao H and Zou Z: Targeting PAX8 sensitizes
ovarian cancer cells to ferroptosis by inhibiting glutathione
synthesis. Apoptosis. 29:1499–1514. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu C, Barger CJ and Karpf AR: FOXM1: A
multifunctional oncoprotein and emerging therapeutic target in
ovarian cancer. Cancers (Basel). 13:30652021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Battistini C, Kenny HA, Zambuto M, Nieddu
V, Melocchi V, Decio A, Lo Riso P, Villa CE, Gatto A, Ghioni M, et
al: Tumor microenvironment-induced FOXM1 regulates ovarian cancer
stemness. Cell Death Dis. 15:3702024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Taki M, Abiko K, Baba T, Hamanishi J,
Yamaguchi K, Murakami R, Yamanoi K, Horikawa N, Hosoe Y, Nakamura
E, et al: Snail promotes ovarian cancer progression by recruiting
myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat
Commun. 9:16852018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu J, Shu G, Wu A, Zhang X, Zhou Z,
Alvero AB, Mor G and Yin G: TWIST1 induces proteasomal degradation
of beta-catenin during the differentiation of ovarian cancer
stem-like cells. Sci Rep. 12:156502022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sestito R, Tocci P, Roman C, Di Castro V
and Bagnato A: Functional interaction between endothelin-1 and
ZEB1/YAP signaling regulates cellular plasticity and metastasis in
high-grade serous ovarian cancer. J Exp Clin Cancer Res.
41:1572022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Looyenga BD, Resau J and MacKeigan JP:
Cytokine receptor-like factor 1 (CRLF1) protects against
6-hydroxydopamine toxicity independent of the gp130/JAK signaling
pathway. PLoS One. 8:e665482013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pasquin S, Laplante V, Kouadri S, Milasan
A, Mayer G, Tormo AJ, Savin V, Sharma M, Martel C and Gauchat JF:
Cardiotrophin-like cytokine increases macrophage-foam cell
transition. J Immunol. 201:2462–2471. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yu ST, Zhong Q, Chen RH, Han P, Li SB,
Zhang H, Yuan L, Xia TL, Zeng MS and Huang XM: CRLF1 promotes
malignant phenotypes of papillary thyroid carcinoma by activating
the MAPK/ERK and PI3K/AKT pathways. Cell Death Dis. 9:3712018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Crisponi L, Buers I and Rutsch F: CRLF1
and CLCF1 in development, health and disease. Int J Mol Sci.
23:9922022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yu ST, Sun BH, Ge JN, Shi JL, Zhu MS, Wei
ZG, Li TT, Zhang ZC, Chen WS and Lei ST: CRLF1-MYH9 interaction
regulates proliferation and metastasis of papillary thyroid
carcinoma through the ERK/ETV4 axis. Front Endocrinol (Lausanne).
11:5352020. View Article : Google Scholar : PubMed/NCBI
|
